In February, a New inhalation triple therapy for the treatment of chronic obstructive pulmonary disease (COPD) with the potential to reduce 52% of episodes of moderate or severe exacerbation of the disease compared to previous treatments, such as double bronchodilating therapy – which uses two different types of bronchodilators, a type of medicine that dilates airways, facilitating breathing.
The therapy was developed by Biopharmaceutical Astrazeneca and combines two types of bronchodilators-Formoterol Fumarate (Labo-Beta-2-long action), glycopirrion bromide (mud-long-acting muscarinic antagonist)-and a corticoid-the buysonide (glycorticosteroid with anti-inflammatory effect)-in a single bomb.
“Triple therapy is as we call today a treatment that combines three different medications that, preferably, should be used in the same bomb,” explains José Eduardo Caçado, professor of pneumology at the Faculty of Medical Sciences of Santa Casa de São Paulo, CNN .
“This triple therapy is indicated for that patient who [no tratamento da DPOC] He is already using two bronchodilators, but persists having crises, even stopping smoking, having vaccines up to date and practicing physical activity, which are non -pharmacological treatments, ”he adds.
What is COPD?
COPD is a progressive and debilitating disease characterized by airway narrowing, occurring pulmonary emphysema, chronic obstructive bronchitis or both conditions together. Its symptoms include persistent cough, increased mucus production and shortness of breath.
The disease is considered the third leading cause of death in the world, being very related to smoking, although it can occur in people who have never smoked.
In Brazil, it is estimated that 14 million people live with the disease, but only 34% have the diagnosis. Without proper identification and treatment, patients may have acute and serious respiratory events, characterized by the increase and worsening of symptoms.
This picture is recognized as an exacerbation or episode of crisis and, without treatment, can lead to other health complications.
“When I compare an individual who has chronic obstructive pulmonary disease with someone the same age, but who does not have this disease, this individual will have more heart disease [doenças cardíacas]such as heart failure, infarction, arrhythmia, among others, ”says Cançado. “This happens for various mechanisms. One of them is chest hyperinsuflation, ie increased air volume within the chest [devido à dificuldade para respirar e pelo estreitamento das vias áreas] Compresses the heart, increasing the risk of coronary insufficiency, ”he adds.
In addition, the patient with COPD suffers an inflammation of the roads that, with the advancement of the disease, can extend to blood vessels. This risk is even greater in those who smoke. “The individual who smokes has an inflammation in the blood vessels. This inflammation causes it to have a greater tendency to blood clotting, increasing the risk of obstruction and, consequently, a stroke, ”he adds.
New treatment reduces episodes of severe exacerbation and hospitalizations for the disease
As a result, in addition to improving the patient’s quality of life, proper COPD treatment reduces the risk of disease crises, related health complications and death.
“The arrival of a new triple inhalation therapy, which significantly reduces exacerbations, contributes considerably to the better control of the disease and the reduction of mortality,” says Cançado.
The new triple therapy has the potential to reduce the rate of hospital hospitalizations per COPD by 20% and by 49% the mortality rate for all causes compared to treatment via double inhalation of inhalation. Time to the first moderate or severe exacerbation was also significantly prolonged compared to the use of this double therapy.
The new treatment uses a technology that favors the uniform deposition of the fine particles of drug walls. In other words, the medicines present in the bomb can reach the central and peripheral areas of the lung, spreading more evenly in the organ. In addition, it was associated with low deposition in the throat region, reducing discomfort, the risk of side effects and increasing the effectiveness of treatment.
Regulatory approval was based on the findings of the study Kronos and Ethosconducted to evaluate the effectiveness and safety of inhalation triple therapy in relation to pulmonary function parameters and moderate or severe exacerbations rate, respectively. In both tests, the safety and tolerability of triple therapy were consistent with comparators’ profiles with therapies.
“As a reference in respiratory disease care, we are committed to developing solutions that reduce exacerbations, hospitalizations, loss of patients’ quality of life and even COPD mortality rates, collaborating in the search for better care of these diseases that are so impactful for patients, their families and the health ecosystem. We are confident that the arrival of the new triple therapy in Brazil will contribute to reducing this impact caused by COPD ”, comments Karina Fontão, executive director of Astrazeneca Brasil.
Obesity and smoking in adolescence indicate future cardiovascular health
This content was originally published in COPD: new therapy that reduces 52% of the disease crises arrives in Brazil on CNN Brazil.
Source: CNN Brasil
I am an experienced journalist and writer with a career in the news industry. My focus is on covering Top News stories for World Stock Market, where I provide comprehensive analysis and commentary on markets around the world. I have expertise in writing both long-form articles and shorter pieces that deliver timely, relevant updates to readers.
